Immunotherapy and Pathology: Biomarkers and Analysis Techniques
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 608
Special Issue Editor
Interests: hematopathology; glial and central nervous system cancer; gastrointestinal tumor; lung cancer; thyroid cancer; genitourinary cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunotherapy, a biological therapy that uses substances to stimulate or suppress the immune system to help the body against some human pathological diseases, is one of the most promising approaches to cancer treatment. The biological basis of this type of treatment is represented by the interaction between tumor and immune system in what is defined as the tumor microenvironment, consisting of various cellular protagonists and soluble mediators. In this way, the development, validation, and clinical implementation of cancer immunotherapy biomarkers is a topic milestone in the selection of patients who can benefit most from this type of therapy. Predictive immunotherapy biomarkers such as programmed death ligand-1 (PD-L1), mismatch repair (MMR), IHC, and microsatellite instability (MSI) testing are already established as routine testing in many pathology laboratories around the world, with other biomarkers (such as TMB) and technologies still in the validation phase. As immunotherapy gains in complexity and is used in combination with radio-chemotherapy and target therapy, anatomic and molecular pathologists play an increasingly important part in identifying and quantifying cellular and molecular biomarkers in tissue samples that reflect the nature and magnitude of the anti-tumor immune response.
Dr. Maurizio Martini
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Immunotherapy
- tumor immune microenvironment
- immuno-response biomarkers
- tumor–immune interaction
- immune biomarker analysis techniques
